JoelSchlessingerMDFAAD, FAACS, FAAP

Dermatology • Omaha, NE

Acne & Rosacea, Cosmetic Dermatology, Dermatologic Surgery

Skin Specialists PC/LovelySkin

Join to view full profile

Dr. Schlessinger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Schlessinger's full profile

Already have an account?

Office
2802 Oak View Drive
Omaha, NE 68144
Phone+1 402-334-7546

Fax+1 402-334-8627
Is this information wrong?

Summary

I am a board-certified dermatologist, cosmetic surgeon and pediatrician as well as the CEO of LovelySkin.com, the 12th largest online seller of cosmetics based on Internet Retailer data.
Professional distinctions include being one of six founders of the American Society of Cosmetic Dermatology and Aesthetic Surgery (ASCDAS), past president of ASCDAS, past president of the Nebraska Dermatology Society and author of multiple articles in reference dermatology literature.
In addition, my clinic has an active research department, having performed over 250 clinical trials since 1993, ranging from neurotoxin trials to filler trials as well as psoriasis, acne, eczema and device trials.
Along with my son, Daniel Schlessinger MD, I developed FixMySkin 1% Hydrocortisone Balm, a patented stick which contains 1% hydrocortisone. This has been covered by the New York Times, Allure. It has sold over 250,000 units.

Education & Training

Washington University/B-JH/SLCH ConsortiumResidency, Dermatology, 1989 - 1992
University of Alabama, Children’s Hospital of AlabamaResidency, Board Certified, 1986 - 1988
University of Alabama Medical CenterResidency, Pediatrics, 1985 - 1988
University of Alabama, Children’s Hospital of AlabamaInternship, 1985 - 1986
Baylor College of MedicineClass of 1985, MD
Brown University Medical SchoolBasic Sciences, Med School, 1981 - 1983
University of Rhode IslandB.A, Biology, Summa Cum Laude, 1980

Certifications & Licensure

HI State Medical License 2009 - 2026
NV State Medical License 2014 - 2025
TN State Medical License 1986 - 2024
NE State Medical License 1992 - 2024
IA State Medical License 1992 - 2006
TX State Medical License 1986 - 1992
AL State Medical License Active through 1991
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Best in Omaha in Cosmetic Surgery Omaha Magazine, 2000-2023
Regional Top Doctor Castle Connolly, 2023
Marquis Who’s Who in America 2006-2015, 2015
Best Doctors in America 2011-2015
Elle ‘Genius’ Selection 2011
Fellow (FASDS) American Society for Dermatologic Surgery
Fellow (FAAD) American Academy of Dermatology
Winner, Best Dermatologist in Omaha Readers Choice/WOWT Awards/Omaha Magazine
Selected one of American’s Top Physicians, Dermatology
Join now to see all

Clinical Trials

Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Start of enrollment: 2006 Dec 01
Completed
Phase 3
Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens Start of enrollment: 2007 Mar 01
Completed
Phase 4
Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines Start of enrollment: 2007 Jun 18
Completed
Phase 3
Phase 2 Study for the Treatment of Superficial Lipomas Start of enrollment: 2007 Nov 01
Completed
Phase 2
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines Start of enrollment: 2008 Oct 01
Completed
Phase 3
Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study Start of enrollment: 2009 Dec 01
Completed
Phase 2
Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis Start of enrollment: 2010 Apr 01
Completed
Phase 2
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults Start of enrollment: 2010 May 01
Completed
Phase 2
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2011 Mar 01
Completed
Phase 3
A Study to Assess Injection Comfort of Two Formulations of ATX-101
Completed
Phase 1
Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis Start of enrollment: 2011 Jun 01
Completed
Phase 3
An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects Start of enrollment: 2014 Jan 01
Completed
Phase 2
Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea Start of enrollment: 2014 May 01
Completed
Not Applicable
Mirvaso in Use Study Start of enrollment: 2014 Sep 01
Completed
Phase 4
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006 Start of enrollment: 2015 May 01
Completed
Phase 2
Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat Start of enrollment: 2016 Dec 22
Completed
Phase 2
A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Feb 20
Completed
Phase 3
Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI) Start of enrollment: 2020 Jun 29
Active, not recruiting
Phase 2
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Start of enrollment: 2021 Sep 20
Completed
Phase 2
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period Start of enrollment: 2023 Nov 06
Recruiting
Phase 3
Roles: Principal Investigator
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Start of enrollment: 2023 Oct 23
Recruiting
Phase 2
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata Start of enrollment: 2023 Feb 27
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Safety and Effectiveness of a Novel Hyaluronic Acid Gel for Lip Augmentation.
Jeffery Adelglass, Javier Alonso-Llamazares, Jeremy Fenton, Joel Schlessinger, Stacy Smith, Gold, M.> ;Journal of Drugs in Dermatology. 2022 Jan 1
6 citations
Collagenase Clostridium Histolyticum-aaes for Treatment of Cellulite: A Pooled Analysis of Two Phase-3 Trials.
Lawrence S Bass, Joely Kaufman-Janette, John H Joseph, Michael S Kaminer, James Clark, Sabrina G Fabi, Michael H Gold, Bruce E Katz, Kappa Peddy, Joel Schlessinger, V ...> ;Plastic and Reconstructive Surgery. Global Open. 2022 May 1
3 citations
AbobotulinumtoxinA Treatment of Glabellar Lines Using a New Reconstitution and Injection Volume: Randomized, Placebo-Controlled Data.
Joel Schlessinger, Daniel P. Friedmann, Flor A Mayoral, Deanne Mraz Robinson, DeeAnna Glaser, Douglas C. Wu, Keith Marcus, Michael Somenek, Xiaoming Lin> ;Journal of Drugs in Dermatology. 2021 Sep 1
8 citations
Efficacy and Safety of a New Resilient Hyaluronic Acid Filler in the Correction of Moderate-to-Severe Dynamic Perioral Rhytides: A 52-Week Prospective, Multicenter, Co...
Hema Sundaram, Ava Shamban, Joel Schlessinger, Joely Kaufman-Janette, John H Joseph, Mark Lupin, Zoe Diana Draelos, Wayne D. Carey, Stacy Smith, Laura Eaton> ;Dermatologic Surgery. 2021 Sep 30
Corrigendum to: The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe ...
Joely Kaufman-Janette, Rui L Avelar, Brian S Biesman, Zoe Diana Draelos, John E Gross, Derek H Jones, Mary P Lupo, Corey S Maas, Joel Schlessinger, Ava Teresa Shamban,...> ;Aesthetic Surgery Journal. 2021 Nov 12
16 citations
Collagenase Clostridium Histolyticum-aaes for the Treatment of Cellulite in Women: Results From Two Phase 3 Randomized, Placebo-Controlled Trials.
Joely Kaufman-Janette, John H Joseph, Michael S. Kaminer, James S. Clark, Sabrina G. Fabi, Michael H. Gold, Mitchel P. Goldman, Bruce E. Katz, Kappa Peddy, Joel Schles...> ;Dermatologic Surgery. 2021 May 1
25 citations
Efficacy and Safety of ATX-101 by Treatment Session: Pooled Analysis of Data From the Phase 3 REFINE Trials
Steven H. Dayan, Joel Schlessinger, Kenneth Beer, Lisa Donofrio, Derek H. Jones, Shannon Humphrey, Jean Carruthers, Paul F. Lizzul, Todd M. Gross, Frederick C. Bedding...> ;Aesthetic Surgery Journal. 2018 Aug 16
Corrigendum to: The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe...
Z Paul Lorenc, Jeffrey M Adelglass, Rui L Avelar, Leslie Baumann, Kenneth R Beer, Joel L Cohen, Sue Ellen Cox, Steven H Dayan, Jeffrey S Dover, Jeanine B Downie, Zoe D...> ;Aesthetic Surgery Journal. 2021 Nov 12
3 citations
The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines...
Z Paul Lorenc, Jeffrey M Adelglass, Rui L Avelar, Leslie Baumann, Kenneth R Beer, Joel L Cohen, Sue Ellen Cox, Steven H Dayan, Jeffrey S Dover, Jeanine B Downie, Zoe D...> ;Aesthetic Surgery Journal. 2021 Nov 12
The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines ...
Kaufman-Janette J, Avelar RL, Biesman BS, Draelos ZD, Gross JE, Jones DH, Lupo MP, Maas CS, Schlessinger JT, Shamban AT, Sundaram H, Weinkle SH, Young VL> ;Aesthetic surgery journal. 2021-05-04
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, Ablon G, Martin G, Wang H, Cutler DL, Fang J, Kwan MR, Phase 3 Tirbanibulin for Actinic Keratosis Group> ;The New England journal of medicine.
1 citations
Aesthetic Office Disaster Preparedness and Response Plan.
Joel L Cohen, Steve H Dayan, Mathew M. Avram, Renato Saltz, Suzanne L. Kilmer, Corey S. Maas, Joel Schlessinger> ;Journal of Drugs in Dermatology. 2021 Jan 1
Efficacy and Safety of Systemic Treatments for Skin and Joint Manifestations in Patients With Psoriasis.
William Abramovits, Joel Schlessinger> ;Journal of Drugs in Dermatology. 2020 Mar 1
1 citations
Hydrogen Peroxide Topical Solution, 45% for Common Warts: Phase 2 Efficacy and Safety Trial Results.
Stacy Smith, Stephen K. Tyring, Kimberly Grande, Joel Schlessinger, Michael H. Gold, Stuart D Shanier> ;Journal of Drugs in Dermatology. 2020 Oct 1
31 citations
New Uses of AbobotulinumtoxinA in Aesthetics.
Joel Schlessinger, Erin Gilbert, Joel L Cohen, Joely Kaufman> ;Aesthetic Surgery Journal. 2017 May 1
8 citations
A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines
Joel Schlessinger, Joel L. Cohen, Ava Shamban, Carolyn I. Jacob, Kian Karimi, Corey S. Maas, Vanessa Lane, Sarah Coquis-Knezek, Matthew H Meckfessel> ;Dermatologic Surgery. 2021 Apr 1
Nashville, Tennessee, December 4-7, 2019.
Joel Schlessinger> ;Skinmed. 2020 Aug 1
15 citations
Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core.
Maria-Elena Liosi, S.G. Krimmer, Ana S. Newton, Thomas K. Dawson, David E. Puleo, Kara J. Cutrona, Yoshihisa Suzuki, Joseph Schlessinger, William L. Jorgensen> ;Journal of Medicinal Chemistry. 2020 May 8
31 citations
DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind,...
Vince Bertucci, Nowell Solish, Joely Kaufman-Janette, Steve Yoelin, Ava Shamban, Joel Schlessinger, Daniel Snyder, Conor J. Gallagher, Yan Liu, Gill Shears, Roman G. R...> ;Journal of the American Academy of Dermatology. 2020 Apr 1
Commentary on Microcannula Injection of Large Gel Particle Hyaluronic Acid for Cheek Augmentation and the Correction of Age-Related Midface Contour Deficiencies
Daniel I. Schlessinger, Joel Schlessinger> ;Dermatologic Surgery. 2020 Apr 1
42 citations
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisA...
Joel Schlessinger, Julie S. Shepard, Richard G. Gower, John C Su, Charles Lynde, Amy Cha, William C. Ports, Vivek S. Purohit, Liza Takiya, John L. Werth, Chuanbo Zang,...> ;American Journal of Clinical Dermatology. 2020 Apr 1
34 citations
DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Stu...
Borsuk, D. E., Jean Carruthers, Steve Fagien, John H. Joseph, Shannon Humphrey, Brian S. Biesman, Conor J. Gallagher, Yan Liu, Roman G. Rubio, Joel L. Cohen, Stephen H...> ;Plastic and Reconstructive Surgery. 2020 Jan 1
5 citations
Safety and Effectiveness of Microfocused Ultrasound for Treating Erythematotelangiectatic Rosacea
Joel Schlessinger, Mark Lupin, David H. McDaniel, Rosalyn George> ;Journal of Drugs in Dermatology. 2019 Jun 1
8 citations
Final Data from the Condition of Submental Fullness and Treatment Outcomes Registry (CONTOUR)
Melanie D. Palm, Joel Schlessinger, Valerie D. Callender, Steven Fagien, Kenneth Beer, Suzanne Magante, Sara Sangha> ;Journal of Drugs in Dermatology. 2019 Jan 1
23 citations
Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placeb...
Leslie Baumann, Andrew Blauvelt, Zoe Diana Draelos, Steven Kempers, Mary P. Lupo, Joel Schlessinger, Stacy Smith, David Wilson, Mark Bradshaw, Esther Estes, Stuart D. ...> ;Journal of the American Academy of Dermatology. 2018 Nov 1
Join now to see all

Lectures

Cosmetic Surgery Forum - Discussions in Dermatology
Cosmetic Surgery Forum, Las Vegas, Nevada - 11/29/2012

Press Mentions

10 Ingredients That Can Help Fight Signs of Premature Skin AgingSeptember 24th, 2021
Which Probiotic for Which Disease? Part 1August 7th, 2021
Rinvoq Has Quicker Onset, Higher EASI Scores Than Dupixent in Phase 3b Study of Adults with Atopic DermatitisAugust 4th, 2021
Join now to see all

Committees

member, ASDS Membership Workgroup Committee 2010 - 2014

Research History

Advanced Skin Research CenterDirector of the Advanced Skin Research Center, Omaha, Nebraska. Have conducted over 250 clinical trials including botulinum toxin, fillers, psoriasis, acne, skin cancer and eczema trials.1994 - Present